First-in-human administration of terbium-161-labelled somatostatin receptor subtype 2 antagonist ([161Tb]Tb-DOTA-LM3) in a patient with a metastatic neuroendocrine tumour of the ileum.

This article reports on the first-in-human administration of terbium-161-labelled somatostatin receptor subtype 2 antagonist ([161Tb]Tb-DOTA-LM3) in a patient with a metastatic neuroendocrine tumor of the ileum. The patient had previously received long-acting octreotide and underwent a test infusion of [161Tb]Tb-DOTA-LM3. The study found that [161Tb]Tb-DOTA-LM3 showed promising potential as an alternative to the current standard peptide receptor radionuclide therapy for patients with metastatic gastroenteropancreatic neuroendocrine tumors. The research was funded by the Swiss National Science Foundation and supported by other organizations. The study was conducted in accordance with ethical guidelines and the patient provided informed consent. [Extracted from the article]